Healthcare provider profile · identity verified

John Eyre, MD

Internal Medicine · WESTLAKE, OH · NPI 1285733964

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	971	276
Amlodipine Besylate	Amlodipine Besylate	434	120
Losartan Potassium	Losartan Potassium	383	104
Levothyroxine Sodium	Levothyroxine Sodium	331	95
Omeprazole	Omeprazole	275	89
Lisinopril	Lisinopril	274	85
Carvedilol	Carvedilol	261	77
Fluticasone Propionate	Fluticasone Propionate	205	101
Simvastatin	Simvastatin	194	55
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	178	47
Metoprolol Succinate	Metoprolol Succinate	174	49
Escitalopram Oxalate	Escitalopram Oxalate	158	50
Montelukast Sodium	Montelukast Sodium	143	41
Pantoprazole Sodium	Pantoprazole Sodium	142	45
Potassium Chloride	Potassium Chloride	135	45
Metformin Hcl	Metformin Hcl	130	39
Gabapentin	Gabapentin	115	44
Tamsulosin Hcl	Tamsulosin Hcl	110	41
Rosuvastatin Calcium	Rosuvastatin Calcium	108	38
Eliquis	Apixaban	105	32
Sertraline Hcl	Sertraline Hcl	104	28
Bupropion Xl	Bupropion Hcl	93	26
Hydrochlorothiazide	Hydrochlorothiazide	91	24
Albuterol Sulfate Hfa	Albuterol Sulfate	88	31
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	85	24
Atenolol	Atenolol	84	23
Alendronate Sodium	Alendronate Sodium	80	25
Citalopram Hbr	Citalopram Hydrobromide	72	22
Allopurinol	Allopurinol	70	18
Prednisone	Prednisone	67	48
Famotidine	Famotidine	63	25
Pravastatin Sodium	Pravastatin Sodium	63	20
Meloxicam	Meloxicam	62	24
Mounjaro	Tirzepatide	61	suppressed
Mirtazapine	Mirtazapine	60	21
Nifedipine Er	Nifedipine	60	16
Doxazosin Mesylate	Doxazosin Mesylate	55	18
Trazodone Hcl	Trazodone Hcl	54	19
Clopidogrel	Clopidogrel Bisulfate	53	16
Metoprolol Tartrate	Metoprolol Tartrate	53	15
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	51	14
Furosemide	Furosemide	50	16
Synthroid	Levothyroxine Sodium	50	18
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	47	40
Finasteride	Finasteride	44	12
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	41	13
Vitamin D2	Ergocalciferol (Vitamin D2)	40	13
Labetalol Hcl	Labetalol Hcl	39	suppressed
Metformin Hcl Er	Metformin Hcl	36	11
Tramadol Hcl	Tramadol Hcl	35	12
Cephalexin	Cephalexin	33	28
Mupirocin	Mupirocin	33	24
Chlorthalidone	Chlorthalidone	32	suppressed
Torsemide	Torsemide	32	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	31	11
Lovastatin	Lovastatin	31	suppressed
Duloxetine Hcl	Duloxetine Hcl	30	11
Trulicity	Dulaglutide	30	suppressed
Baclofen	Baclofen	29	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	29	27
Hydroxyzine Hcl	Hydroxyzine Hcl	29	14
Ipratropium Bromide	Ipratropium Bromide	27	11
Zolpidem Tartrate	Zolpidem Tartrate	25	suppressed
Buspirone Hcl	Buspirone Hcl	24	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	24	24
Lansoprazole	Lansoprazole	23	suppressed
Warfarin Sodium	Warfarin Sodium	23	suppressed
Alprazolam	Alprazolam	22	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	22	22
Meclizine Hcl	Meclizine Hcl	22	13
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	22	19
Glimepiride	Glimepiride	21	suppressed
Lidocaine	Lidocaine	21	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	21	14
Benazepril Hcl	Benazepril Hcl	20	suppressed
Tizanidine Hcl	Tizanidine Hcl	20	13
Clotrimazole	Clotrimazole	19	13
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	19	suppressed
Xarelto	Rivaroxaban	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Glipizide	Glipizide	18	suppressed
Azithromycin	Azithromycin	17	15
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	17	suppressed
Folic Acid	Folic Acid	17	suppressed
Myrbetriq	Mirabegron	17	suppressed
Raloxifene Hcl	Raloxifene Hcl	17	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Ibuprofen	Ibuprofen	16	suppressed
Methocarbamol	Methocarbamol	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Amoxicillin	Amoxicillin	15	12
Celecoxib	Celecoxib	15	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Fenofibrate	Fenofibrate,micronized	15	suppressed
Spiriva Handihaler	Tiotropium Bromide	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Valsartan	Valsartan	15	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	14	suppressed
Klor-Con M10	Potassium Chloride	13	suppressed
Ramipril	Ramipril	13	suppressed
Terazosin Hcl	Terazosin Hcl	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	12	suppressed
Latanoprost	Latanoprost	12	suppressed
Lorazepam	Lorazepam	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Wegovy	Semaglutide	12	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Ozempic	Semaglutide	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error